Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for SAB Biotherapeutics, Inc. (SABS : NSDQ)
 
 • Company Description   
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress Acquisition Corp., is based in SIOUX FALLS, S.D.

Number of Employees: 63

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.76 Daily Weekly Monthly
20 Day Moving Average: 13,357 shares
Shares Outstanding: 9.29 (millions)
Market Capitalization: $16.35 (millions)
Beta: 0.52
52 Week High: $5.01
52 Week Low: $1.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.38% -8.85%
12 Week 53.04% 23.04%
Year To Date -53.61% -55.98%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
777 W 41st St Suite 401
-
Miami Beach,FL 33140
USA
ph: 605-679-6980
fax: -
kgardner@lifesciadvisors.com http://www.sabbiotherapeutics.com
 
 • General Corporate Information   
Officers
Samuel J. Reich - Chairman of the Board and Chief Executive Officer
Eddie J. Sullivan - President
Christoph Bausch - Chief Operating Officer
Lucy To - Chief Financial Officer
Erick Lucera - Director

Peer Information
SAB Biotherapeutics, Inc. (CORR.)
SAB Biotherapeutics, Inc. (RSPI)
SAB Biotherapeutics, Inc. (CGXP)
SAB Biotherapeutics, Inc. (BGEN)
SAB Biotherapeutics, Inc. (GTBP)
SAB Biotherapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 78397T202
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 9.29
Most Recent Split Date: 1.00 (0.10:1)
Beta: 0.52
Market Capitalization: $16.35 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.80 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.76
Price/Cash Flow: -
Price / Sales: 5.88
EPS Growth
vs. Year Ago Period: -3.70%
vs. Previous Quarter: 54.47%
Sales Growth
vs. Year Ago Period: -62.35%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -105.14
12/31/24 - -84.31
ROA
06/30/25 - -
03/31/25 - -69.24
12/31/24 - -58.99
Current Ratio
06/30/25 - -
03/31/25 - 1.69
12/31/24 - 2.98
Quick Ratio
06/30/25 - -
03/31/25 - 1.69
12/31/24 - 2.98
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -9,067.72
12/31/24 - -2,579.80
Book Value
06/30/25 - -
03/31/25 - 2.30
12/31/24 - 2.81
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.15
12/31/24 - 0.13
Debt-to-Capital
06/30/25 - -
03/31/25 - 13.14
12/31/24 - 11.20
 

Powered by Zacks Investment Research ©